51 completed, 24 terminated, 21 active not recruiting, 17 recruiting. 73 Phase 2, 58 Phase 1, 7 Phase 3, 3 Early Phase 1, 2 Phase 4.
Follow binimetinib: new trials by email Literature Review of binimetinib trials Research Report on binimetinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Surgical or Radiotherapeutic Intervention Concerning Large Singular Stable to Progressive Metastases in Patients With BRAFV600-mutated Melanoma Receiving Treatment With Encorafenib + Binimetinib Encorafenib & Binimetinib Treatment - Melanoma BRAF V600E/K Mutated | Phase 4 | Withdrawn | SRH Wald-Klinikum Gera GmbH | 2025-08-01 | 2026-04-21 | |
| UK ENcorafenib and BInimetinib Real-world Study in Melanoma Encorafenib + Binimetinib - Metastatic Melanoma, BRAF V600 Mutation Positive | Active not recruiting | Pierre Fabre Ltd | 50 | 2025-07-31 | 2026-04-13 | |
| Encorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant melanOma and Symptomatic Brain Metastases Encorafenib + Binimetinib, cemiplimab+fianlimab - Melanoma BRAF V600E/K Mutated, Melanoma and Brain Metastases | Phase 2 | Recruiting | Grupo Español Multidisciplinar de Melanoma | 33 | 2025-05-29 | 2025-10-01 |
| Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial) Binimetinib, Biopsy Procedure, Biospecimen Collection - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 1 | 2024-09-13 | 2026-03-03 |
| Personalized Medicine for Advanced Biliary Cancer Patients Futibatinib, Ivosidenib, Zanidatamab - Biliary Tract Neoplasms | Phase 3 | Recruiting | UNICANCER | 800 | 2024-07-18 | 2026-05-19 |
| Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial) Binimetinib, Biopsy Procedure, Biospecimen Collection - Advanced Biliary Tract Carcinoma, Advanced Gallbladder Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 17 | 2024-02-09 | 2026-10-19 |
| Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic Cancer Binimetinib, Palbociclib, Therapeutic Conventional Surgery - Colorectal Carcinoma, Lung Adenocarcinoma | Early Phase 1 | Withdrawn | Roswell Park Cancer Institute | 2024-01-15 | 2023-12-22 | |
| Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial Binimetinib, Biopsy Procedure, Biospecimen Collection - Exocrine Pancreas Carcinoma, Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 199 | 2023-12-13 | 2026-08-21 |
| Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma Pembrolizumab, Encorafenib, Binimetinib - Malignant Melanoma, Metastatic Melanoma | Phase 2 | Completed | Dr. Ronnie Shapira | 1 | 2023-09-05 | 2025-07-22 |
| A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma encorafenib, binimetinib, pembrolizumab - Melanoma | Phase 2 | Terminated | Pfizer | 38 | 2023-06-13 | 2026-03-09 |
| MEKTOVI® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma Binimetinib Oral Tablet [Mektovi] - Adamantinous Craniopharyngioma, Recurrent Adamantinomatous Craniopharyngioma | Phase 2 | Recruiting | Nationwide Children's Hospital | 38 | 2023-04-10 | 2026-04-08 |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial Alpelisib, Binimetinib, Biopsy Procedure - Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8 | Phase 2 | Recruiting | National Cancer Institute (NCI) | 2900 | 2023-04-07 | 2026-10-15 |
| Binimetinib in Patients With BRAF Fusion-positive Low-grade Glioma or Pancreatic Cancer (Perfume) Binimetinib 15 MG - Low-grade Glioma, Pancreatic Cancer | Phase 2 | Recruiting | National Cancer Center, Japan | 32 | 2023-03-29 | 2023-12-13 |
| Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis Stereotaxic radiosurgery (SRS), Binimetinib Oral Tablet, Encorafenib Oral Capsule - Malignant Melanoma, BRAF V600 Mutation | Phase 2 | Active not recruiting | UNICANCER | 10 | 2022-09-05 | 2026-06-05 |
| Neoadjuvant Encorafenib, Binimetinib and Cetuximab for Patients With BRAF V600E Mutated/pMMR Localized Colorectal Cancer Binimetinib - Colorectal Cancer, Colon Cancer | Phase 2 | Completed | AIO-Studien-gGmbH | 2 | 2022-09-01 | 2025-10-01 |
| Bioequivalence Binimetinib 3 x 15 mg and 45 mg Formulations Binimetinib 15 MG, Binimetinib 45 MG - Melanoma, BRAF V600 Mutation | Phase 1 | Completed | Pierre Fabre Medicament | 37 | 2022-08-31 | 2024-09-19 |
| Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer BET Bromodomain Inhibitor ZEN-3694, Binimetinib, Biopsy Procedure - Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 1 | Recruiting | National Cancer Institute (NCI) | 42 | 2022-08-02 | 2026-10-14 |
| A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations. PF-07799933, binimetinib, cetuximab - Melanoma, Non-Small-Cell Lung Cancer | Phase 1 | Active not recruiting | Pfizer | 103 | 2022-07-05 | 2026-09-01 |
| The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials Binimetinib, Encorafenib, Vemurafenib - Solid Tumors | Phase 4 | Recruiting | Pfizer | 210 | 2022-07-05 | 2026-10-19 |
| Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer Encorafenib, Binimetinib - Non-Small Cell Lung Cancer | Phase 2 | Active not recruiting | Pierre Fabre Medicament | 63 | 2022-06-02 | 2026-05-01 |
Showing 20 of 125. Sign in to see all of them.
Melanoma (47) · Carcinoma, Non-Small-Cell Lung (16) · Colorectal Neoplasms (14) · Lung Neoplasms (11) · Neoplasm Metastasis (10) · Brain Neoplasms (9) · Pancreatic Neoplasms (9) · Neoplasms (8) · Triple Negative Breast Neoplasms (6) · Colonic Neoplasms (5) · Skin Neoplasms (5) · Ovarian Neoplasms (4) · Rectal Neoplasms (4) · Biliary Tract Neoplasms (3) · Breast Neoplasms (3)
Pfizer (26) · National Cancer Institute (NCI) (9) · Array Biopharma, now a wholly owned subsidiary of Pfizer (8) · Pierre Fabre Medicament (7) · H. Lee Moffitt Cancer Center and Research Institute (4) · M.D. Anderson Cancer Center (4) · Memorial Sloan Kettering Cancer Center (4) · Jonsson Comprehensive Cancer Center (3) · University Health Network, Toronto (3) · University of California, San Francisco (3) · Academic and Community Cancer Research United (2) · Deciphera Pharmaceuticals, LLC (2) · Grupo Español Multidisciplinar de Melanoma (2) · Peter MacCallum Cancer Centre, Australia (2) · UNICANCER (2)
United States (88) · Spain (28) · Canada (23) · Italy (23) · France (22) · United Kingdom (20) · Australia (19) · Germany (19) · Netherlands (18) · Belgium (15) · Switzerland (13) · Poland (9) · Austria (8) · Czechia (8) · Israel (8)
Marina Klein, MD (2) · Ping Chi, MD, PhD (2) · Robert J Kreitman, M.D. (2) · Ahmad Tarhini, MD, PhD (1) · Alexander Stein, Prof. Dr. (1) · Alfonso Berrocal Jaime, M.D. (1) · Amit Oza, MD (1) · Andrew E Hendifar (1) · Andrew Furness, MBBS, MRCP, PhD (1) · Anna Spreafico, MD (1) · Antoni Ribas (1) · Ardaman Shergill (1)
PMID 34655839, PMID 35385748, PMID 19942357, PMID 23414587, PMID 26112811, PMID 26586415, PMID 27288470, PMID 28284557, PMID 28592387, PMID 29573941, PMID 30181415, PMID 30219628, PMID 30892987, PMID 31213500, PMID 31312030, PMID 31395751, PMID 31437754, PMID 31566309, PMID 32379297, PMID 32463741, PMID 32669376, PMID 32822286, PMID 33048619, PMID 33503393, PMID 34052705, PMID 34091420, PMID 34376578, PMID 34625515, PMID 34774225, PMID 34918546, PMID 34986285, PMID 35041493, PMID 35133871, PMID 35138919, PMID 35272485, PMID 35294522, PMID 35653981, PMID 35654691, PMID 35862871, PMID 36049147, PMID 36351402, PMID 36608320, PMID 36653241, PMID 36653848, PMID 36763936, PMID 37053535, PMID 37186063, PMID 37270692, PMID 37309702, PMID 37322121
2018 (4), U10CA180820 (4), 2014 (2), 2017 (2), 2023 (2), P30CA015083 (2), U10CA180821 (2), U24CA196172 (2), 2015 (1), 2019 (1), P01CA168585 (1), R01CA258751 (1), U10CA180868 (1), U10CA180888 (1), UM1CA137443 (1)